Fast-Dissolving Freeze Dried Sublingual Wafer as a Novel Drug Delivery System
Currently, active compounds (e.g. pharmaceutical and/or nutraceutical active ingredients) are administered intravenously, intramuscularly or orally. These conventional methods of administration have their own shortcomings. For example, intravenous administration often requires an expensive clinical setting, is invasive, painful and not suitable for individuals who have a phobia of needles. Oral administration (e.g. via the consumption of capsules, tablets, mixtures and suspensions) is also not a suitable method for the delivery of active compounds which are effectively lost during hepatic (first-pass liver metabolism) and/or gastrointestinal metabolism, a process that affects the bioavailability of numerous active compounds when ingested orally. Oral ingestion can also delay the onset of a therapeutic effect by several hours.
The technology is a proprietary wafer formulation that allows pharmaceutical and/or nutraceutical active compounds to be administered sublingually, allowing for these compounds to be delivered safely, rapidly and conveniently into the blood stream. The technology is a superior mode of delivery as it reduces the effects of hepatic and gastrointestinal metabolism. Using the technology, sublingual delivery increases the rate and predictability of already approved drugs, resulting in an increase of new and improved clinical applications.